Product Description
Ruxolitinib is in a class of medications called kinase inhibitors. It works to treat myelofibrosis and PV by blocking the signals that cause cancer cells to multiply. This helps to stop the spread of cancer cells. It works to treat GVHD by blocking the signals of the cells that cause GVHD.
Mechanisms of Action: JAK1 Inhibitor,JAK2 Inhibitor,STAT Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Canada | Chile | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: Myelofibrosis | Polycythemia | Thrombocythemia, Essential | Polycythemia Vera | Dermatitis | Dermatitis, Atopic | Vitiligo
Known Adverse Events: Dizziness | Headache | Anemia | Thrombocytopenia | Dermatitis | Erythema | Folliculitis | Urticaria | Nasopharyngitis | Pharyngitis | Tonsillitis | Dermatitis, Atopic | Pruritus | Vitiligo | Bronchitis | Diarrhea
Company: Incyte
Company Location: WILMINGTON DE 19803
Company CEO: Hervé Hoppenot
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, Chile, China, Croatia, Czech Republic, Denmark, Finland, France, Germany, Greece, Hong Kong, Hungary, India, Ireland, Israel, Italy, Japan, Korea, Malaysia, Netherlands, New Zealand, Norway, Poland, Puerto Rico, Romania, Russia, Serbia, Slovakia, South Africa, Spain, Sweden, Switzerland, Taiwan, Thailand, Turkey, Ukraine, United Kingdom, United States, Unknown Location
Active Clinical Trial Count: 123
Highest Development Phases
Phase 3: Acute Lymphoid Leukemia|Acute Myeloid Leukemia|Allogeneic Stem Cell Transplant|Anemia|Dermatitis, Atopic|Graft vs Host Disease|Myelodysplastic Syndrome|Myelofibrosis|Neurodermatitis|Polycythemia Vera|Precursor Cell Lymphoblastic Leukemia-Lymphoma|Prurigo|Thrombocythemia, Essential|Thrombocytosis|Thrombosis|Vitiligo
Phase 2: Acute Monocytic Leukemia|Acute Myelomonocytic Leukemia|Acute Respiratory Distress Syndrome|Blast Crisis|Breast Cancer|Breast Diseases|Bronchiolitis Obliterans|COVID-19|Chronic Myelomonocytic Leukemia|Colorectal Cancer|Dermatitis|Dermatitis, Seborrheic|Ductal Breast Carcinoma|Ductal Carcinoma|Eosinophilia|Exanthema|Head and Neck Cancer|Hepatitis B, Chronic|Hepatomegaly|Hidradenitis Suppurativa|Hodgkin Lymphoma|Hypereosinophilic Syndrome|Inflammatory Breast Cancer|Intraductal Noninfiltrating Carcinoma|Juvenile Myelomonocytic Leukemia,|Lichen Planus|Lichen Sclerosus et Atrophicus|Lobular Carcinoma|Lung Cancer|Lupus Erythematosus, Discoid|Lupus Erythematosus, Systemic|Lymphohistiocytosis, Hemophagocytic|Lymphoid Leukemia|Lymphoma, Non-Hodgkin|Multiple Myeloma|Myeloproliferative Disorders|Pancreatic Cancer|Skin Manifestations|Squamous Cell Carcinoma
Phase 1: Adenocarcinoma|Cachexia|Chronic Myeloid Leukemia|Cytokine Release Syndrome|Healthy Volunteers|Myelogenous, Chronic, BCR-ABL Positive Leukemia|Non-Small-Cell Lung Cancer|Oncology Unspecified|Pancreatic Ductal Carcinoma|Wasting Syndrome
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| TRANSFORM-2 | P3 |
Active, not recruiting |
Myelofibrosis |
2031-11-25 |
|
| HEM-iSMART C | P2 |
Not yet recruiting |
Acute Lymphoid Leukemia|Lymphoma, Non-Hodgkin|Precursor Cell Lymphoblastic Leukemia-Lymphoma |
2031-10-01 |
|
| 2020-002071-35 | P2 |
Active, not recruiting |
Myelofibrosis |
2030-10-26 |
|
| INCA34176-254 | P2 |
Not yet recruiting |
Unknown |
2030-01-31 |